Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes
Authors
Keywords
-
Journal
HYPERTENSION RESEARCH
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-19
DOI
10.1038/s41440-020-0426-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Uric acid and the cardio‐renal effects of SGLT2 inhibitors
- (2019) Clifford J. Bailey DIABETES OBESITY & METABOLISM
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
- (2019) Kengo Kidokoro et al. CIRCULATION
- GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
- (2019) Lesley A. Inker et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Clinical features and therapeutic perspectives on hypertension in diabetics
- (2018) Shigehiro Katayama et al. HYPERTENSION RESEARCH
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
- (2018) Atsutaka Yasui et al. Diabetes Therapy
- Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
- (2018) Atsutaka Yasui et al. Diabetes Therapy
- Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
- (2018) Kenjiro Kimura et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8
- (2018) Yumi Takiyama et al. EBioMedicine
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive MedicationNovelty and Significance
- (2016) Giuseppe Mancia et al. HYPERTENSION
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal effects of canagliflozin in type 2 diabetes mellitus
- (2015) Vlado Perkovic et al. CURRENT MEDICAL RESEARCH AND OPINION
- Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2015) Yutaka Seino et al. ENDOCRINE JOURNAL
- Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
- (2015) Yutaka Seino et al. Journal of Diabetes Investigation
- Effect of Acetazolamide on Obesity-Induced Glomerular Hyperfiltration: A Randomized Controlled Trial
- (2015) Boris Zingerman et al. PLoS One
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values
- (2012) Atsunori Kashiwagi et al. Journal of Diabetes Investigation
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
- (2011) Scott C. Thomson et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
- Revised Equations for Estimated GFR From Serum Creatinine in Japan
- (2009) Seiichi Matsuo et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now